Symbols

VERU

Veru·NASDAQ

--(--)

VERU fundamentals

VERU Q1 2026 Earnings

Veru (VERU) released its earnings on Feb 11, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.26 (YoY +56.67%), beat estimates.

Revenue / YoY

EPS / YoY

-0.26

+56.67%

Report date

Feb 11, 2026

VERU Earnings Call Summary for Q1,2026

FDA-Backed Dual Pathways: Enobosarm can seek approval via 5% incremental weight loss or preservation of physical function, with validated 3mg dosage.
PLATEAU Study Launched: 200-patient trial to assess enobosarm's ability to break weight loss plateau with semaglutide; interim analysis at 34 weeks for lean/fat mass trends.
Financial Stability: $33M cash balance post-public offering, supporting operations through key interim analysis.
Strategic Focus: Enobosarm's dual potential to enhance weight loss quality and preserve bone density positions it for differentiated obesity treatment.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Veru (VERU) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Veru (VERU)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Veru (VERU)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Veru (VERU)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown